Figure 2.Distribution of SLC10A3 transcription among different clinical groups. (A) age. (B) gender. (C) race. (D) WHO grade. (E) IDH mutation status. (F) 1p19q co-deletion. (G) laterality. (H) histological type. (I) primary therapy outcome.
Figure 2 — The prognostic significance and immune correlation of SLC10A3 in low-grade gliomas revealed by bioinformatic analysis and multiple immunohistochemistry | Aging
